5th INTERNATIONAL CONFERENCE
ON FUTURE TRENDS IN THE
TREATMENT OF BRAIN TUMORS
November 8th-9th 2013, Hotel Royal Carlton, Bologna (Italy)

CHAIRPERSON
Alba A. Brandes

ORGANIZING SECRETARIAT
AIM GROUP INTERNATIONAL - AIM Meeting S.r.l.
Via G. Ripamonti, 129 - 20141 Milan (Italy)
PHONE: +39 02 56601845
FAX: +39 02 70048590
Email: a.sanna@aimgroup.eu
aimgroupinternational.com

Unrestricted educational grant of
Roche
Dear Colleagues and Friends,

Welcome to the 5th International Conference on Future Trends in the Treatment of Brain Tumors. Launched in 2001, this international conference aims to foster the advancement of scientific knowledge that may ultimately result in a better prognosis for our patients. It provides an important forum for the exchange of knowledge and experience amongst the clinicians and researchers involved in brain tumour research and patient management. Gliomas are malignant diseases associated with poor prognosis and they are a key focus area for cancer research. However, despite significant advances in standard therapy, new treatments are urgently needed.

Accelerating the transition of promising laboratory findings from bench to bedside is providing exciting results – from clinical trials right through to point-of-care patient applications. The identification of oncogenic driver mutations and the underlying sensitivity to novel agents has led to a surge of interest in identifying additional targetable oncogenes in gliomas. A number of new potentially oncogenic gene alterations have been characterized in recent years, including IDH1/2 mutations. During this conference, we will discuss the prevalence of these genetic alterations, as well as the potential prognostic role in gliomas.

Knowledge of aberrant signalling pathways in gliomas has provided hope for new potential therapeutic targets. Many preclinical studies use brain tumours such as glioma as a model of angiogenesis, and recent findings have indicated that vascular endothelial growth factor (VEGF) plays a role in the development of gliomas. These neoplasms are highly vascular and elevated expression levels of VEGF have been correlated with biologic aggressiveness and poorer clinical outcomes. On the other hand, angiogenesis inhibition in primary and recurrent GBM is a potentially important treatment pathway that could provide meaningful health outcomes to patients.

Innovative therapeutic approaches are based on a greater understanding of molecular and cellular biology, and this educational event will review the very latest basic research findings. The internationally renowned speakers at this conference will also explore the clinical aspects of current neuro-oncology research, neuroradiological response evaluation, quality of life issues and comprehensive patient care that takes into account the patient’s needs.

I look forward to joining you in the enchanting city of Bologna to discuss these important topics. I am confident that together we can make this conference an enjoyable and collaborative event where we can share our scientific and clinical knowledge in the hope of improving our patients’ lives.

Yours sincerely,

Alba A. Brandes
CHAIRPERSON
Alba A. Brandes, Dept. of Medical Oncology, AUSL - IRCCS Institute of Neurological Sciences, Bologna, Italy

FACULTY
Raffaele Agati, Dept. of Neuroradiology, AUSL - IRCCS Institute of Neurological Sciences, Bologna, Italy
Giovanni Apolone, IRCCS Arcispedale S. Maria Nuova Hospital, Reggio Emilia, Italy
Carmen Balaña Quintero, Dept. of Medical Oncology, ICO - Hospital Germans Trias i Pujol, Badalona, Spain
Agostino Baruzzi, Scientific Director, IRCCS Institute of Neurological Sciences, Bologna, Italy
Tracy T. Batchelor, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, USA
Brigitta Baumert, MediClin Robert Janker Klinik, Dept. Radiotherapy and Radiation Oncology & University of Bonn Med Centre, Cooperation Unit Neuro-Oncology, Maastricht, The Netherlands
Antoine Carpentier, Dept. of Neurology, Avicenne Hospital, Paris XIII University, Bobigny, France
Oliver Chinot, Dept. of Neuro-Oncology, Timone Center University Hospital, University of the Mediterranean, Marseille, France
Lisa M. DeAngelis, Dept. of Neurology, Memorial Sloan-Kettering Cancer Center (MSKCC) & Professor of Neurology, Weill Medical College of Cornell University, New York, USA
John De Groot, Dept. of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
Guettano Finocchiaro, Dept. of Molecular Neuro-Oncology, IRCCS Foundation, Besta Neurological Institute, Milan, Italy
Pim J. French, Dept. of Neurology, Erasmus MC Cancer Center, Rotterdam, The Netherlands
Giovanni P. Frezza, Dept. of Oncological Radiotherapy, AUSL - IRCCS Institute of Neurological Sciences, Bologna, Italy
Felice Giangaspero, Institute of Pathological Anatomy, “Umberto I” University Hospital, University “La Sapienza” of Rome, Italy
Mark Gilbert, Dept. of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
Stuart Grossman, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Stefano M. Magrini, Dept. of Radiation Oncology, Spedali Civili Hospital, Brescia, Italy
Warren Mason, The Gerry & Nancy Pencer Brain Tumor Centre, Princess Margaret Hospital, University of Toronto, Canada
Kathy Oliver, Co-Director, International Brain Tumor Alliance (IBTA), Tadworth, Surrey, UK
Andrea Pace, Neurology Unit, Regina Elena National Cancer Institute, Rome, Italy
Josef Pichler, Internal Medicine and Neuro-Oncology, Landesnervenklinik Linz, Austria
David Reardon, Center for Neuro-Oncology, DanaFarber Cancer Institute, Boston, USA
Francesco Ripa Di Meana, General Director, AUSL Bologna, Italy
Fausto Roila, Dept. of Oncology, S. Maria Hospital, Terni, Italy
Marc Sanson, Dept. of Neurology, Pitié-Salpêtrière Hospital, University Pierre and Marie Curie, Paris, France
Frank Saran, Dept. of Radiotherapy, Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK
Carmelo Sturiale, Dept. of Neurosurgery, AUSL - IRCCS Institute of Neurological Sciences, Bologna, Italy
Walter Taal, Dept. of Neurology/Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, The Netherlands
Martin J. Taphoorn, Dept. of Neurology, Medical Center Haaglanden, The Hague Dep. of Neurology, VU University Medical Center, Amsterdam, The Netherlands
Martin J. Van den Bent, Dept. of Neurology/Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, The Netherlands
Michael Weller, Dept. of Neurology, University Hospital Zurich, Switzerland
Patrick Y. Wen, Center for Neuro-Oncology, DanaFarber Cancer Institute, Boston, USA
Wolfgang Wick, Dept. of Neuro-Oncology, Heidelberg University Hospital, Heidelberg, Germany
### 5th International Conference on Future Trends in the Treatment of Brain Tumors

**November 8th-9th 2013, Hotel Royal Carlton, Bologna (Italy)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 p.m.</td>
<td>12:00 p.m.</td>
<td>Welcome lunch</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>1:00 p.m.</td>
<td>Participants registration</td>
<td></td>
</tr>
<tr>
<td>1:10 p.m.</td>
<td>1:10 p.m.</td>
<td>Welcome address</td>
<td>A. Baruzzi (Bologna), F. Ripa di Meana (Bologna)</td>
</tr>
<tr>
<td>1:20 p.m.</td>
<td>1:20 p.m.</td>
<td>Introduction</td>
<td>A.A. Brandes (Bologna)</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>1:30 p.m.</td>
<td>Primary and secondary glioblastoma</td>
<td>F. Giangaspero (Rome)</td>
</tr>
<tr>
<td>1:50 p.m.</td>
<td>1:50 p.m.</td>
<td>The mechanism of anti-angiogenic inhibitor therapies in glioblastoma</td>
<td>J. De Groot (Houston)</td>
</tr>
<tr>
<td>2:10 p.m.</td>
<td>2:10 p.m.</td>
<td>New approaches to the treatment of newly diagnosed GBM patients</td>
<td>O. Chinot (Marseille)</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>2:30 p.m.</td>
<td>New therapeutic approaches for newly diagnosed GBM patients: RTOG perspectives</td>
<td>M. Gilbert (Houston)</td>
</tr>
<tr>
<td>2:50 p.m.</td>
<td>2:50 p.m.</td>
<td>How to interpret clinical trials in newly diagnosed GBM patients</td>
<td>W. Wick (Heidelberg)</td>
</tr>
<tr>
<td>3:10 p.m.</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>3:40 p.m.</td>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

### Session I

**Glioblastoma**

Moderators: P.J. French (Rotterdam), G.P. Frezza (Bologna), W. Mason (Toronto), F. Saran (Sutton)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.</td>
<td>1:30 p.m.</td>
<td>Primary and secondary glioblastoma</td>
<td>F. Giangaspero (Rome)</td>
</tr>
<tr>
<td>1:50 p.m.</td>
<td>1:50 p.m.</td>
<td>The mechanism of anti-angiogenic inhibitor therapies in glioblastoma</td>
<td>J. De Groot (Houston)</td>
</tr>
<tr>
<td>2:10 p.m.</td>
<td>2:10 p.m.</td>
<td>New approaches to the treatment of newly diagnosed GBM patients</td>
<td>O. Chinot (Marseille)</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>2:30 p.m.</td>
<td>New therapeutic approaches for newly diagnosed GBM patients: RTOG perspectives</td>
<td>M. Gilbert (Houston)</td>
</tr>
<tr>
<td>2:50 p.m.</td>
<td>2:50 p.m.</td>
<td>How to interpret clinical trials in newly diagnosed GBM patients</td>
<td>W. Wick (Heidelberg)</td>
</tr>
<tr>
<td>3:10 p.m.</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Session II

Moderators: A. Carpentier (Bobigny), F. Roila (Terni)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 p.m.</td>
<td>4:00 p.m.</td>
<td>Future trials in newly diagnosed GBM</td>
<td>A.A. Brandes (Bologna)</td>
</tr>
<tr>
<td>4:20 p.m.</td>
<td>4:20 p.m.</td>
<td>Future trials in elderly GBM</td>
<td>M. Weller (Zurich)</td>
</tr>
<tr>
<td>4:40 p.m.</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Session III

Moderators: G. Apolone (Reggio Emilia), A. Pace (Rome)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:55 p.m.</td>
<td>4:55 p.m.</td>
<td>Quality of life in gliomas</td>
<td>M.J. Taphoorn (The Hague)</td>
</tr>
<tr>
<td>5:15 p.m.</td>
<td>5:15 p.m.</td>
<td>Quality of life and clinical trial outcomes in newly diagnosed GBM</td>
<td>W. Mason (Toronto)</td>
</tr>
<tr>
<td>5:35 p.m.</td>
<td>5:35 p.m.</td>
<td>Clinical management of anti-angiogenic inhibitor therapy in patients with brain tumours</td>
<td>S. Grossman (Baltimore)</td>
</tr>
<tr>
<td>5:55 p.m.</td>
<td>5:55 p.m.</td>
<td>The brain tumour patient and caregiver: what really matters on the journey?</td>
<td>K. Oliver (Tadworth)</td>
</tr>
<tr>
<td>6:15 p.m.</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>6:30 p.m.</td>
<td></td>
<td>Close day 1</td>
<td></td>
</tr>
</tbody>
</table>
5th INTERNATIONAL CONFERENCE ON FUTURE TRENDS IN THE TREATMENT OF BRAIN TUMORS
November 8th- 9th 2013, Hotel Royal Carlton, Bologna (Italy)

SESSION I
RECURRENT GLIOBLASTOMA: EVALUATION OF PROGRESSION
Moderators: R. Agati (Bologna), C. Balaña Quintero (Badalona), W. Taal (Rotterdam)

08:45 a.m. Rano criteria
P.Y. Wen (Boston)

09:05 a.m. Nano criteria
D. Reardon (Boston)

09:25 a.m. Glioblastoma recurrence: news from ASCO 2013
T.T. Batchelor (Boston)

09:45 a.m. Discussion

AWARD SESSION
Moderators: A.A. Brandes (Bologna), S.M. Magrini (Brescia), J. Pichler (Linz)

10:00 a.m. Award for the best clinical work published in the last 3 years

10:30 a.m. Coffee break

SESSION II
LOW GRADE AND ANAPLASTIC GLIOMAS
Moderators: G. Finocchiaro (Milan), S. Grossman (Baltimore), C. Sturiale (Bologna)

10:45 a.m. Can molecular markers help with decision-making?
M. Sanson (Paris)
SCIENTIFIC INFORMATION

OFFICIAL LANGUAGE
English

SLIDES
Only computer video projection will be available. Other requirements should be communicated to the Scientific Secretariat as soon as possible. The presentations should be handed into the Slide Center on pen drive one hour before the beginning of the session, and collected at the end.

BADGE
All registered participants, speakers and attendants will be given a badge which they must wear to be admitted to the scientific sessions.

ATTENDANCE CERTIFICATE
A certificate will be given to all attendants at the end of the conference.

CME
Accreditation has been requested for MDs working in oncology, neuro-oncology, neurology, radiotherapy, neuroradiology, pathological anatomy departments and for nurses.

GENERAL INFORMATION

CONFERENCE VENUE
SALA IMPERIALE
HOTEL ROYAL CARLTON
VIA MONTEBELLO 8, 40121 BOLOGNA
PHONE +39 051 – 249361

HOW TO REACH THE CONFERENCE VENUE
The Royal Hotel Carlton is in the centre of Bologna, near the pedestrian area, outside the restricted traffic zone and just a short walk from the railway station and Piazza Maggiore.
Walking distance: Bologna railway station.
By taxi: 15 minutes (5 km) from Bologna airport.
By car: to reach the hotel using satellite navigation, it should be set for Via Milazzo 6 to avoid the restricted traffic zone.

REGISTRATION
The registration is free of charge. Preference will be given to pre-registered attendants. Please return the pre-registration form to the Scientific Secretariat.

McCANN Complete Medical
Via Aosta 4/a, 20153 Milan, Italy
PHONE: +39 02 5416951 FAX: +39 02 54169554,
Email: segreteria@complete-italy.it
REGISTRATION FORM

The registration is free of charge.
Please return this form to the Scientific Secretariat:

McCANN Complete Medical
Via Aosta 4/a, 20155 Milan, Italy
PHONE: +39 02 5416951  FAX: +39 02 54169554
E-mail: segreteria@complete-italy.it

LAST NAME
FIRST NAME
POSITION TITLE
INSTITUTION
PRIVATE ADDRESS
ZIP CODE
CITY
STATE/PROVINCE
COUNTRY
PHONE
FAX
MOBILE PHONE
EMAIL
TAX PAYER’S NUMBER [FISCAL CODE]

Signing this form and well informed on the legislative Decree n. 196/2003 concerning “Personal data processing”, I authorize McCann Complete Medical until written revocation, to process and divulge my personal data within the limits of the above-mentioned law and in accordance with the procedure laid down by the law. I give my assent provided that McCann Complete Medical complies with the regulations in force.

☑️ I do not want that my personal data are divulged to third parties.

Date: ___________________________ Signature: ___________________________
INTRODUCTION
The young investigator Award illustrate the dedication of the 5th International Congress on future trends in the treatment of brain tumors to support original research and scientific excellence. The Young Investigator Award is conferred to one young Medical Oncologist, not older than 40 years of age by the end of the year in which the Award is given, in recognition of her or his scientific publications on the treatment of brain tumors. The award is given on the basis of a selection from submissions received from applicants.

HOW TO APPLY
An applicant must submit the following informations in the format below:
• One original paper, published or accepted for publication, in an international peer-reviewed journal in the last three years. The candidates must be the first author.
• An up-to-date CV and a list of publications.

ELIGIBILITY
All applications must be submitted electronically, by ordinary mail or FAX, to the Scientific Secretary at:
McCann Complete Medical - Via Aosta 4/a - 20155 Milan, Italy
Object: Young Investigator Award – 5th International Conference on Future Trends in the Treatment of Brain Tumors
FAX: +39 02 54169554
E-mail: segreteria@complete-italy.it
All applicants will be acknowledged by email.

EVALUATION
The decisions taken by the Committee are based on the overall quality of the candidate’s CV, and especially on the original publication submitted by each applicant. The successful applicant will be notified by the Committee before the “5th International Congress on future trends in the treatment of brain tumors” and will be awarded during the Congress.
### YOUNG INVESTIGATOR AWARD

**APPLICATION FORM**

[To be submitted electronically to segreteria@complete-italy.it]

<table>
<thead>
<tr>
<th>NAME OF APPLICANT</th>
<th>____________________________</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROFESSIONAL ADDRESS</td>
<td>____________________________</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DATE OF BIRTH</th>
<th>/ /</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>TELEPHONE No</th>
<th>National code</th>
<th>Regional code</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAX No</td>
<td>National code</td>
<td>Regional code</td>
<td>Number</td>
</tr>
<tr>
<td>E-MAIL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SUBMITTED PAPER** (authors, title, journal reference including first and last page numbers)

1. _________________________________________________________________

Please send your completed application form and supporting documents ELECTRONICALLY to the Scientific Secretariat: segreteria@complete-italy.it

Checklist of items to include:

- Applicant’s CV
- Copy of the paper (pdf)